Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in the treatment of episodic migraine in patients who had previously failed two to four preventive treatments, whether due to ineffectiveness or intolerable side effects.
Reageer